Clarke et al. (2009) have concluded in their study that Thalassaemia Major poses a considerable challenge to the health-related quality of life (HRQOL) in children, which is evident in areas of the world where this disease is prevalent. Despite the availability of financial benefits and care provided by the National Health Service (NHS), their study proves a similar burden in the UK.
In their cross-sectional assessment, child HRQOL was found to be significantly lower than population norms. And family financial concerns associated with this disease were linked with poorer child HRQOL (p = 0.020).
To alleviate the impact of financial concerns and transport issues, the authors (Clarke et al.) have recommended provision of better information about care allowances and help from the social workers to the specific needs of the related population.
Though there are some limitations, like the relatively small sample and dependence on only reports from mothers of the suffering children, this study provides a valuable insight into the common concerns of caring for children with Thalassaemia Major in the UK. 
As content editor from Nursing Essay Help This research can be used as an evidence, for the necessity of policy formulation to ameliorate the quality of life of those having this disease and monitoring the impact of those policies inside the UK.

Diagnosis of Thalassaemia

Modell et al. (2008) have concluded in their study that there has been a marked improvement in survival in Thalassaemia Major in the UK since 1999.
This is due to enhanced diagnosis by the introduction of T2-CMR (cardiovascular magnetic resonance) to identify myocardial siderosis, which is the major cause of death associated with this disease.
Thalassaemia patients need regular blood transfusion to maintain a mean haemoglobin in the normal range; this gives good short-term quality of life, ultimately leading to death from transfusional iron overload between 12 and 24 years of age. 
This hazard has been easily diagnosed by the deployment of T2-CMR, which makes cardiac iron overload clearly visible; and this has been a driver for changes in, and intensification of, existing iron chelation therapy.
In their research, the rate of deaths from iron overload was found to reduce from 7.9 to 2.3 deaths per 1000 patient years (-71%, p < 0.05), which is an extremely good sign.
As the deaths from iron overload seem to be under control from this research, the authors (Modell et al.) have recommended to concentrate on the other causes of mortality, notably infections, which may become the leading causes of death in Thalassaemia in the near future.